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Abstract Immune thrombocytopenia (ITP) is characterised
by a transient or persistent decrease in platelets accompa-
nied by an increased risk of bleeding, which can have a
significant negative impact on patients’ health-related
quality of life. The condition has long been associated with
an increased rate of immune-mediated platelet destruction,
and traditional treatments have targeted the reduction in
platelet destruction; however, some interventional drugs are
limited by transient efficacy and side effects. Recent
advances in our understanding of ITP pathogenesis have
highlighted the role of impaired platelet production, which
has led to the advent of a new generation of thrombopoietin
(TPO)-receptor agonist therapies, including eltrombopag
and romiplostim. The oral, non-peptide TPO-receptor
agonist eltrombopag has shown considerable promise in
both preclinical and clinical trials. Eltrombopag has a
unique mechanism of action and binds to a transmembrane
region of the TPO receptor that is distant from the TPO
binding site. As such, eltrombopag may confer synergistic
effects with endogenous TPO rather than competing for
binding. Eltrombopag also induces activation of the TPO
receptor and downstream signalling in a distinct manner to
TPO and does not have a significant impact on platelet
function. Clinical evidence demonstrates that eltrombopag
produces a rapid and sustainable increase in platelet counts
that significantly reduces bleeding and is well tolerated in
patients with ITP. Eltrombopag therefore represents an
important addition to the therapeutic armamentarium for
ITP.
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Introduction
Immune thrombocytopenia (ITP; formerly idiopathic or
immune thrombocytopenic purpura) is mostly an acquired
cytopenia of adults and children with various aetiologies. It
is characterised by a transient or persistent decrease in
platelets and an increase in the risk of bleeding [1–5]. The
estimated incidence of ITP is 100 cases per 1 million
persons per year, with approximately 50% of these cases
occurring in children [2, 6]. In adults, the incidence is
higher in women than in men [2], whereas the reverse is
true in children, where ITP predominates in young male [7].
Clinical presentation varies from asymptomatic or mild
symptoms (bruising and petechiae) to mucocutaneous
bleeding that can become severe [5, 8].
ITP has long been known to be associated with an
increased rate of immune-mediated platelet destruction. The
exact mechanism of this destruction remains unknown, and
there may be several immune-mediated co-mechanisms [3].
Traditional treatment strategies for patients with ITP have
focused on reducing platelet destruction. However, with
greater insight into the pathophysiology of ITP, it has
become apparent that this disorder results not only from
increased platelet destruction but also from impaired platelet
production [9]. These processes are thought to result from
auto-antibodies targeting both mature platelets and mega-
karyocytes for destruction by macrophages [9]. These new
findings have driven the concept of targeting platelet
stimulation in the treatment of ITP and the subsequent
introduction of a new generation of thrombopoietin (TPO)-
receptor agonists, including eltrombopag and romiplostim.
T. Kühne (*) : P. Imbach
Pediatric Hematology-Oncology, University Children’s Hospital,
Medical Faculty of University of Basel UKBB,
PO Box, CH-4005 Basel, Switzerland
e-mail: thomas.kuehne@ukbb.ch
Ann Hematol (2010) 89 (Suppl 1):S67–S74
DOI 10.1007/s00277-010-0953-x
The role of thrombopoietin in platelet production
Although some platelets are consumed in the haemostatic
process, platelets typically remain in circulation for ap-
proximately 10 days before destruction [10]. In order to
achieve a stable platelet count, platelet production must
equal the rate of platelet consumption and destruction.
Platelet production, or thrombopoiesis, occurs in the bone
marrow where committed stem cells differentiate into
megakaryocytes. Platelets are formed from haematopoietic
stem cells through a series of divisions of progenitor cells,
which ultimately produce the mature megakaryocytes
responsible for platelet release (Fig. 1) [11].
The glycoprotein hormone TPO, produced primarily in
the liver, is the principal regulator of megakaryocyte
development and platelet production (Fig. 1) [11–13].
Thrombopoietin is involved in nearly every stage of
megakaryocyte development, supporting cell survival and
cell cycling, as well as modulating apoptosis and cell cycle
regulators [14]. Thrombopoietin acts by binding and
activating cell surface TPO receptors (also known as c-
Mpl) [11, 15]. The activated TPO receptor undergoes
dimerisation and a conformation change that results in
activation of Janus protein tyrosine kinases (JAK) and
subsequent downstream signalling within the megakaryo-
cyte via signal transducers and activators of transcription
(STAT), phosphoinositide 3-kinase (PI3K), and mitogen-
activated protein kinases (MAPK) effectors. This induces
megakaryocyte proliferation and differentiation, which
leads to increased platelet production [12, 16].
In individuals without ITP, a drop in platelet levels
triggers an increase in TPO in order to stimulate platelet
production and correct the platelet deficit [14, 15, 17–20].
However, measurement of TPO in patients with ITP has
repeatedly shown levels to be within the normal range or
only slightly elevated, and there does not appear to be a
correlation between platelet counts and serum TPO levels
in ITP patients [17, 18, 20]. Thus, the new class of TPO-
receptor agonists aims to increase platelet production by
supplementing the suboptimal levels of endogenous TPO
present in many individuals with ITP.
Treatment for immune thrombocytopenia
The principal aim of treatment for ITP is to achieve a
platelet count that will provide protection against the risk of
major bleeding rather than to correct patients’ platelet
counts to normal levels [21]. Current treatment strategies
are hampered by the heterogeneous nature of ITP with
regard to its severity and clinical course and its unpredict-
able response to therapy. Standard treatment options
include corticosteroids, intravenous immunoglobulins,
anti-D-immunoglobulins and surgical splenectomy; howev-
er, all are limited by their often transient efficacy [2] and
side effects, which can be difficult to tolerate [22].
Splenectomised patients have an increased long-term risk
of infection. Splenectomy is rarely performed in children given
both the increased likelihood of spontaneous and/or therapy-
induced remission and the increased infection-related morbidity
and mortality [23]. Rituximab, a monoclonal anti-CD20
antibody, is an effective immunotherapeutic agent increasingly
used to treat refractory ITP; however, its use is associated with
infusion-related side effects [24, 25], increased risk of the
development of progressive multifocal leukoencephalopathy
[26] and a greater incidence of infections [27].
Current treatments primarily target platelet destruction
[2, 28]. As such, the development of new therapies has
focused on stimulation of platelet production, including
Fig. 1 The role of cytokines in megakaryocytopoiesis. Many stages
of megakaryocyte development can be affected by several cytokines in
vitro, including steel factor (also termed stem-cell factor, mast-cell
growth factor, or Kit ligand), interleukin-3, interleukin-6, interleukin-
11, granulocyte colony-stimulating factor (G-CSF), erythropoietin,
leukaemia inhibitory factor and thrombopoietin [11]
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growth factor and growth factor analogue stimulation of
megakaryopoiesis [4, 29, 30]. Although the first generation
agents demonstrated efficacy in elevating platelet counts,
some of them were associated with the development of auto-
antibodies that cross-react with, and neutralise, endogenous
TPO, leading to severe thrombocytopenia [30]. Therefore,
research into other agents, including non-peptide TPO-
receptor agonists that do not trigger immunogenicity, was
initiated [30].
In 2008, two new drugs, romiplostim (NplateTM) and
eltrombopag (RevoladeTM, known as Promacta® in the
USA and currently under European Medicines Agency
review) that mimic the effect of TPO became available to
treat adults with chronic ITP [31]. Romiplostim is a peptide
mimetic given by subcutaneous injection that activates the
TPO receptor via a similar mechanism to TPO, resulting in
increases in platelet count in healthy humans as well as in
over 80% of patients with ITP [31]. Eltrombopag is a novel
oral, small molecule (molecular weight 442.5 Da for the
free acid), synthetic non-peptide TPO-receptor agonist that
has shown considerable promise in preclinical and clinical
trials, with increases in platelet counts to ≥50,000/µL
reported in 59–87% of patients with ITP [32–35].
Eltrombopag
Eltrombopag displays receptor-specific and species-specific
binding
In preclinical studies, eltrombopag has been shown to
stimulate human megakaryocyte differentiation and prolif-
eration in a dose-dependent manner, via stimulation of the
TPO receptor [36].
Eltrombopag displays high receptor- and species-specific
binding selectivity for the human TPO receptor. The
response of normal human TPO receptors has been
elucidated by measuring growth and differentiation of
human bone marrow in vitro. These studies demonstrated
human and chimpanzee-specific stimulation of TPO-
receptor-expressing cells via activation of STAT5, with no
eltrombopag-induced STAT activation observed in other
species tested, including cynomolgus macaques, rhesus
monkeys, pigs, dogs, ferrets, rabbits, rats and mice [36].
The selectivity of eltrombopag for the TPO-receptor rather
than other growth factor receptors was demonstrated by
assays measuring STAT activation or reporter gene expres-
sion in various transfected and non-transfected cell lines.
The assays confirmed the ability of eltrombopag to activate
signalling in cells expressing the TPO receptor but showed
that it had no effect on cells expressing only interferon-γ,
granulocyte macrophage-colony stimulating factor (GM-
CSF), G-CSF, erythropoietin or interleukin-3 receptors
[36]. The fact that eltrombopag lacks activity against cells
expressing growth factor receptors other than TPO, even
those acting through the JAK/STAT signalling pathway,
suggests that the activation of JAK/STAT by eltrombopag is
due to the specific activation of the TPO receptor [37].
Additional studies have demonstrated that eltrombopag
specificity can also be observed at a cellular level. In ex
vivo experiments, eltrombopag effectively increased mega-
karyocytic colony formation from mature and immature
megakaryocyte progenitors [38]. However, treatment with
eltrombopag did not result in a significant change in
differentiation nor maturation characteristics of the granu-
locytic/monocytic or the erythrocytic lineages, indicating
that eltrombopag preferentially acts on progenitor and
precursor cells harbouring megakaryocytic potential [38].
Thus, eltrombopag is a true agonist of the human TPO
receptor that is able to act on megakaryocytes and their
progenitors in a manner similar to TPO with the potential to
induce differentiation and proliferation of megakaryocytes
and ultimately relieve thrombocytopenia [37].
Eltrombopag: unique mechanism of action
While both eltrombopag and romiplostim act as TPO
agonists, their mechanisms of action differ, since they bind
and activate the TPO receptor in different ways [39].
Romiplostim binds directly to the receptor in the same
manner as endogenous TPO and initiates downstream
signalling in a similar manner to endogenous TPO [39].
In vitro studies have demonstrated that romiplostim com-
petes with endogenous TPO for binding [40]. In contrast,
eltrombopag interacts with the TPO receptor at a binding
site distant from that of TPO and appears to initiate signal
transduction by a mechanism different from that of
endogenous TPO [39] (Fig. 2). Since eltrombopag and
TPO do not bind to the same site, competitive binding is
avoided, and eltrombopag and TPO confer additive cell-
signalling effects [37] (Fig. 2).
The ultimate responses to eltrombopag are similar to
those observed with endogenous TPO with stimulation of
transcription through STAT-based and megakaryocyte-
specific promoters [37]. However, studies have reported
some differences in activation of downstream targets of the
TPO receptor between eltrombopag and human recombi-
nant TPO (hrTPO). In vitro studies have shown that while
treatment with hrTPO leads to a significant increase of both
STAT3 and STAT5 phosphorylation, cells treated with
eltrombopag respond with an increase in STAT5 phosphor-
ylation only, while p-STAT3 levels remain consistent with
levels observed in untreated controls [38]. In their signal
transduction studies, Erhardt et al. reported that eltrombo-
pag induced the phosphorylation of STAT proteins, but not
of Akt, whereas hrTPO induced the phosphorylation of Akt
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in addition to the STAT proteins [41]. These findings
suggest that the effect of eltrombopag appears to be distinct
from hrTPO or other TPO mimetics in some respects and
may be explained by eltrombopag’s unique binding site on
the TPO receptor.
TPO and eltrombopag may also differ with regard to
their effects on platelet activation. In vitro, TPO primes
platelets to aggregate in the presence of other substances,
such as adenosine diphosphate or collagen, which stimulate
platelet aggregation [42]. Although it is unclear whether
platelet ‘priming’ represents any risk for patients, it may
pose a risk in patients prone to thrombogenic conditions
[11]. Eltrombopag stimulates platelet production with little
or no effect on platelet function. In vitro and ex vivo studies
using platelet samples from healthy volunteers and patients
with chronic ITP have shown that eltrombopag has no
effect on platelet aggregation or activation [41, 43] and that
platelet function with eltrombopag is comparable to that
with placebo [43]. The clinical relevance of these findings
is unknown at present.
Clinical experience with eltrombopag
Consistent with its proposed mechanism of action, eltrom-
bopag has demonstrated efficacy with a well-tolerated
safety profile in an extensive clinical trial program of over
400 patients with chronic ITP in phase II and III studies
(Table 1).
Efficacy
In adults with chronic ITP, eltrombopag therapy (50 mg/day
once daily) has been shown to rapidly increase platelet
counts to haemostatic levels (>50 × 109/L) within 15 days,
with over 50% of patients achieving platelet counts
≥50 × 109/L on day 43 (Fig. 3) [34]. Responses are
achieved regardless of baseline platelet levels, concomitant
ITP therapy or splenectomy status [33, 34]. In the long-term
Randomised Placebo-Controlled ITP Study with Eltrombo-
pag (RAISE), from day 15 throughout treatment, median
platelet counts were between 52 and 91×109/L for patients
treated with eltrombopag; in contrast, median platelet
counts for the placebo group never exceeded 30×109/L
[44].
Eltrombopag therapy was also associated with a signif-
icant reduction in the incidence of World Health Organisa-
tion (WHO)-defined bleeding [45]. In the 6-month RAISE,
treatment with eltrombopag was associated with a 76%
reduction in the odds of bleeding (WHO grades 1–4) over
6 months compared with placebo [OR, 0.24 (95% CI, 0.16–
0.38); p<0.001] and a 65% reduction in the odds of
clinically significant bleeding (WHO grades 2–4) over
6 months compared with placebo [OR, 0.35 (95% CI, 0.19–
0.64); p<0.001) [45].
Eltrombopag therapy may also allow ITP patients to
discontinue concomitant medications and reduce their
rescue medication usage. In the 6-month RAISE, more
patients receiving eltrombopag stopped or dose-reduced
Fig. 2 Cellular mechanism of
action of eltrombopag. Eltrom-
bopag binds to a transmembrane
domain of the TPO-receptor
distal from the TPO binding site
to initiate TPO signalling by a
distinct mechanism that leads to
increased platelet production
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their concomitant ITP medications versus placebo (59 vs
32%; p=0.016), and significantly fewer patients required
rescue therapy with eltrombopag versus placebo (19 vs
40%; p=0.001) [45]. In the Eltrombopag Extended Dosing
(EXTEND) study, 70% of patients who responded to
eltrombopag were able to discontinue their concomitant
ITP medication or had a sustained reduction in their
baseline ITP medication and did not require subsequent
rescue medication [46].
The efficacy of eltrombopag against the symptoms of
ITP translated into improvements in health-related quality
of life measures. Results from the 6-month RAISE study
showed that patients receiving eltrombopag reported mean-
ingful improvements in vitality, emotional and physical role
domains and in overall mental health [47]. Eltrombopag-
treated patients consistently reported clinically and statisti-
cally significant benefits in physical and social activities
and concerns around bleeding and bruising symptoms.
They also perceived a reduction in fatigue symptoms and
an improved ability to participate in activities of daily
living [47, 48].
Safety
Eltrombopag was generally well tolerated in clinical trials,
with an adverse event (AE) profile that was comparable to
that of placebo. In the phase II and III trials, the incidence
and severity of AEs with eltrombopag were similar to those
reported with placebo, with most events being mild to
moderate in severity. Headache was reported to be the most
common AE (incidence, 8–30%) [33, 34, 45]. In RAISE, a
higher incidence of hepatobiliary laboratory abnormalities
were reported in the eltrombopag- (13%) versus placebo-
treated patients (7%) [45], and the gastrointestinal system
was the most commonly affected system [45]. The most
common serious adverse event was haemorrhage; most
haemorrhagic events occurred when platelet counts were
decreasing after cessation of eltrombopag therapy [33, 34,
45]. Although transient decreases in platelet counts below
baseline levels were reported in several eltrombopag-treated
patients in the phase III trial, these were not accompanied
by clinically meaningful increases in bleeding [34]. In the
long-term EXTEND study, where the median time on
eltrombopag treatment was 91.5 days (range, 2–523 days),
seven patients experienced thromboembolic events; four of
these events were considered to be related to study
medication [32]. Five patients had reticulin, and two
patients had reticulin in conjunction with collagen fibres
documented in the bone marrow; three of these patients had
documentation of pre-existing reticulin fibres [32].
Eltrombopag was also well tolerated upon repeated
administration in the Repeat Exposure to Eltrombopag
in Adults with Idiopathic Thrombocytopenic Purpura
(REPEAT) study [35] and as long-term therapy in the 6-
month RAISE and the ongoing open-label phase III
extension EXTEND studies, in which the safety profiles
were similar to those reported in the 6-week phase III
studies [32, 34, 45, 49].
Conclusions
Although often considered a benign condition, ITP has a
significant negative impact on patients’ health-related
quality of life, and this impact is often exacerbated by the
adverse effects of traditional treatments such as cortico-
steroids [34]. Recent advances in our understanding of
chronic ITP have highlighted the key role of impaired
platelet production in the pathogenesis of the condition, and
this in turn has led to the advent of a new class of TPO-
receptor agonist therapies.
The oral, non-peptide TPO-receptor agonist eltrombopag
has shown considerable promise in both preclinical and
clinical trials. Eltrombopag has a unique mechanism of
action, binding to a transmembrane region of the TPO
receptor that is distant from the TPO binding site, meaning
that it may confer synergistic effects with endogenous TPO
rather than competing for binding. It induces activation of
the TPO receptor and downstream signalling in a distinct
manner to TPO and does not have a significant impact on
platelet function. Clinical evidence demonstrates that
eltrombopag is well tolerated in patients with ITP and
produces a rapid and sustainable increase in platelet counts,
which significantly reduces bleeding. Thus, eltrombopag
represents an important addition to the therapeutic arma-
mentarium for ITP and a step toward shifting the treatment
paradigm of ITP to include platelet production in addition
to preventing platelet destruction.
Fig. 3 Proportion of patients who achieved a platelet count of
≥50,000/µL on day 43 following a 6-week treatment period in a
randomized, double-blind, placebo-controlled study of eltrombopag in
patients with chronic ITP [34]
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